Novartis cell treatment named "Breakthrough Therapy" in US

ZURICH, July 7 Mon Jul 7, 2014 1:49pm EDT

ZURICH, July 7 (Reuters) - Swiss drugmaker Novartis said on Monday U.S. health regulators have granted its personalised cell therapy CLT019 "Breakthrough Therapy" status, meaning the treatment will be fast-tracked within the U.S. regulatory system.

The U.S. Food and Drug Administration's "Breakthrough Therapy" designation aims to speed up the review process of medicines that treat serious or life-threatening conditions.

Together with the University of Pennsylvania's Perelman School of Medicine (Penn), Novartis is developing CTL019 as a treatment for patients both young and old with relapsed/refractory acute lymphoblastic leukemia.

CTL019, which is currently in Phase I/II clinical trials, works by engineering a patient's own T-cells to hunt and attack cancer cells that express a specific protein called CD19.

Novartis leads the field at present with these Chimeric Antigen Receptor T-cell, or CAR-T, immunotherapies, and has products in clinical trials for leukaemia, lymphoma, mesothelioma and pancreatic cancer.

(Reporting by Caroline Copley. Editing by Jane Merriman)

A couple walks along the rough surf during sunset at Oahu's North Shore, December 26, 2013. REUTERS/Kevin Lamarque

Find your dream retirement town

Florida? Hawaii? Reuters has teamed up with Zillow to give you the power to customize a list of your best places to retire.  Video | Full Article